[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 338, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 39.34, "open": 37.94, "dayLow": 36.545, "dayHigh": 38.83, "regularMarketPreviousClose": 39.34, "regularMarketOpen": 37.94, "regularMarketDayLow": 36.545, "regularMarketDayHigh": 38.83, "payoutRatio": 0.0, "beta": 2.136, "trailingPE": 248.99998, "forwardPE": 38.505154, "volume": 3128531, "regularMarketVolume": 3128531, "averageVolume": 2696146, "averageVolume10days": 2477580, "averageDailyVolume10Day": 2477580, "bid": 37.24, "ask": 37.5, "bidSize": 1, "askSize": 2, "marketCap": 5866601984, "fiftyTwoWeekLow": 12.93, "fiftyTwoWeekHigh": 43.32, "priceToSalesTrailing12Months": 17.8314, "fiftyDayAverage": 35.2804, "twoHundredDayAverage": 27.750225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5367607808, "profitMargins": 0.07107, "floatShares": 134539735, "sharesOutstanding": 157071008, "sharesShort": 26233481, "sharesShortPriorMonth": 25744460, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.16700001, "heldPercentInsiders": 0.093789995, "heldPercentInstitutions": 0.62731, "shortRatio": 7.84, "shortPercentOfFloat": 0.1843, "impliedSharesOutstanding": 157071008, "bookValue": 1.544, "priceToBook": 24.190413, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 23383000, "trailingEps": 0.15, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 16.315, "enterpriseToEbitda": 127.809, "52WeekChange": 1.4949899, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 37.35, "targetHighPrice": 55.0, "targetLowPrice": 11.0, "targetMeanPrice": 43.0, "targetMedianPrice": 48.0, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 311000000, "totalCashPerShare": 2.141, "ebitda": 41997000, "totalDebt": 254380000, "quickRatio": 4.854, "currentRatio": 6.246, "totalRevenue": 329004000, "debtToEquity": 114.398, "revenuePerShare": 2.264, "returnOnAssets": 0.05777, "returnOnEquity": 0.122150004, "grossProfits": 290518016, "freeCashflow": -62020876, "operatingCashflow": -40517000, "revenueGrowth": 1.46, "grossMargins": 0.88302004, "ebitdaMargins": 0.12765001, "operatingMargins": 0.27683002, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1743810992, "regularMarketTime": 1743796801, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": -1.07094, "postMarketPrice": 36.95, "postMarketChange": -0.399998, "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "marketState": "CLOSED", "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.058469, "regularMarketPrice": 37.35, "epsTrailingTwelveMonths": 0.15, "epsForward": 0.97, "epsCurrentYear": 1.05, "priceEpsCurrentYear": 35.57143, "fiftyDayAverageChange": 2.0695992, "fiftyDayAverageChangePercent": 0.058661442, "twoHundredDayAverageChange": 9.599773, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "regularMarketChange": -1.9900017, "regularMarketDayRange": "36.545 - 38.83", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2696146, "fiftyTwoWeekLowChange": 24.419998, "fiftyTwoWeekLowChangePercent": 1.8886309, "fiftyTwoWeekRange": "12.93 - 43.32", "fiftyTwoWeekHighChange": -5.970001, "fiftyTwoWeekHighChangePercent": -0.13781166, "fiftyTwoWeekChangePercent": 149.499, "earningsTimestamp": 1736861400, "earningsTimestampStart": 1745929800, "earningsTimestampEnd": 1746448200, "earningsCallTimestampStart": 1741008600, "earningsCallTimestampEnd": 1741008600, "isEarningsDateEstimate": true, "twoHundredDayAverageChangePercent": 0.345935, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]